Turnstone stops TIL studies; GH Research’s $150M offering
Plus, news about Auron Therapeutics, Akribion Therapeutics, Enveric Biosciences and Valerio Therapeutics: Turnstone Biologics to discontinue TIL studies, “review strategic alternatives”: The company...
View ArticleIllumina added to China's blacklist following Biosecure Act, tariffs
China added DNA sequencing giant Illumina to a list of blacklisted entities after proposed US legislation targeted two Chinese rivals to Illumina and President Donald Trump imposed a 10% tax on all...
View ArticleTrump undercuts RFK Jr. assurances on vaccines, autism
Robert F. Kennedy Jr. is headed for Senate confirmation following Tuesday’s committee vote and a statement of support from the GOP’s biggest skeptic. But it’s still very, very unclear which Kennedy...
View ArticlePfizer says it has at least $10B available for deals in 2025
Pfizer's next deals are likely to be longer-term efforts to reload its R&D work rather than big-ticket, late-stage assets, the company's top executives said Tuesday. “Looking forward, we are...
View ArticleFDA approves Roche's ocular implant in diabetic macular edema
Roche subsidiary Genentech announced Tuesday that it won FDA approval for its eye implant Susvimo to treat diabetic macular edema, a diabetes complication that causes swelling and blurred vision....
View ArticleJ&J asks court for quick decision in 340B rebate model fight
Johnson & Johnson has asked a federal district court to expedite its decision in a case over the company’s proposed 340B rebate model, citing upcoming deadlines for complying with the Inflation...
View ArticleAmgen announces hold on Phase 1 obesity candidate, pipeline cuts
Amgen said one of its early-stage obesity programs has been put on a clinical hold by the FDA, while reiterating its ambitions to become a major player in the crowded field. The company hasn’t revealed...
View ArticleUpdated: Novo Nordisk sees growth slowing this year, plans CagriSema filing...
Novo Nordisk had a good 2024, but this year might be less stellar. The Danish company’s 2024 sales increased 26% from the year before at constant currency, it said Wednesday, but ...
View ArticleGSK defiant against vaccine challenges, will prioritize other growth areas
GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, which saw full-year 2024 sales slide from the year prior. The drop was...
View ArticleWith first drug now in the clinic, Alys eyes megaround for rest of pipeline
Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi startups — following the clearance of its first clinical trial this week ...
View ArticleEyePoint shares more mid-stage data for therapy trying to compete with...
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron's share of the degenerative eye disease market, said six-month results show its drug met the primary endpoint in a Phase 2...
View ArticleBristol Myers, Kyowa Kirin disclose layoffs
Bristol Myers Squibb lays off 67 staffers in NJ: The company is letting go of 67 workers in Lawrence Township between April and December, according to a New Jersey WARN Notice ...
View ArticleRevance, Crown near deal close after earlier bidding war
The fight over who gets control of Revance Therapeutics and its Botox competitor, Daxxify, is coming to a close. On Wednesday, Revance said it’s moving forward with its sale to Crown Laboratories. The...
View ArticleSmall personalized vaccine trial sees progress in late-stage kidney cancer
All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after about three years of receiving treatment, researchers wrote in a Nature paper
View ArticleNovo Nordisk is feeling the competition from compounded GLP-1s, exec says
Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for Novo Nordisk’s prescriptions, a...
View ArticleKura's AML drug succeeds in advanced patients, will take to FDA
The race is on between Kura Oncology and Syndax Pharmaceuticals. On Wednesday, Kura and its partner Kyowa Kirin announced that their targeted treatment ziftomenib succeeded in a key study for a subset...
View ArticleTeladoc to buy Catapult Health for $65M
Teladoc said it will buy at-home testing company Catapult Health for $65 million on Wednesday to focus more on its longer-term care programs. Catapult Health provides users with a kit to check blood...
View ArticleBristol Myers launches new round of major cost cuts
Less than a year after announcing a major cost-cutting campaign, Bristol Myers Squibb is planning another round that will be even larger. On Thursday, the company said it plans to find $2 billion in...
View ArticleLilly posts 45% sales jump, culls four programs across obesity, Alzheimer's,...
Eli Lilly said Thursday that its fourth-quarter revenue jumped 45% to $13.53 billion over the prior year, though this fell short of earlier projections. The drugmaker also reiterated the $58 billion to...
View Article